Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Atezolizumab + Bevacizumab |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Atezolizumab | Tecentriq | RG7446|MPDL3280A | Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112 | Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in PD-L1 positive (IC >/= 5%) advanced or metastatic urothelial carcinoma not eligible for cisplatin-containing chemotherapy, in advanced or metastatic urothelial carcinoma not eligible for chemotherapy, in metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, as first-line therapy in metastatic NSCLC with high PD-L1 expression (TC>/=50% or IC>/=10%) and without EGFR or ALK alterations, for adjuvant treatment in patients with PD-L1-positive (>=1% tumor cell expression) NSCLC, in combination with bevacizumab, paclitaxel, and carboplatin as first-line therapy for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound and carboplatin in metastatic non-squamous NSCLC with no EGFR or ALK aberrations, in combination with carboplatin and etoposide in extensive-stage small cell lung cancer, in combination with bevacizumab in hepatocellular carcinoma without prior systemic therapy, in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib) in unresectable or metastatic BRAF V600-mutated melanoma, and in pediatric and adult patients with unresectable or metastatic alveolar soft part sarcoma (FDA.gov). |
| Bevacizumab | Avastin | VEGF Antibody 11 VEGFR Inhibitor (Pan) 36 | Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
| NCT04510584 | Phase II | Atezolizumab + Bevacizumab | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer | Withdrawn | CAN | 0 |
| NCT03434379 | Phase III | Atezolizumab + Bevacizumab Sorafenib | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 9 |
| NCT05180006 | Phase II | Atezolizumab Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab | Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program) | Recruiting | FRA | 0 |
| NCT03526432 | Phase II | Atezolizumab + Bevacizumab | Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | Active, not recruiting | USA | 0 |
| NCT05488522 | Phase I | Atezolizumab + Bevacizumab | SBRT With Atezo/Bev for HCC | Recruiting | USA | 0 |
| NCT03424005 | Phase Ib/II | Atezolizumab + Bevacizumab + Selicrelumab Atezolizumab + RO6874281 Atezolizumab + Bevacizumab Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Eribulin Capecitabine Atezolizumab Atezolizumab + Bevacizumab + Cobimetinib Atezolizumab + Capecitabine Atezolizumab + Ipatasertib Atezolizumab + Ladiratuzumab vedotin | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) | Recruiting | USA | GBR | FRA | ESP | DEU | AUS | 2 |
| NCT03896074 | Phase II | Atezolizumab + Bevacizumab Atezolizumab | Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT) | Unknown status | ITA | 0 |
| NCT03654833 | Phase II | Bemcentinib + Pembrolizumab Rucaparib Abemaciclib Atezolizumab + Bevacizumab Dostarlimab-gxly + Niraparib | Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (MiST) | Active, not recruiting | GBR | 0 |
| NCT04803994 | Phase III | Atezolizumab + Bevacizumab | The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | Recruiting | ESP | DEU | AUT | 0 |
| NCT03175432 | Phase II | Atezolizumab + Bevacizumab | Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases (BEAT-MBM) | Active, not recruiting | USA | 0 |
| NCT03272217 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | Terminated | USA | 0 |
| NCT06096779 | Phase II | Atezolizumab + Bevacizumab Atezolizumab | A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis (Kirros) | Recruiting | USA | 0 |
| NCT04356729 | Phase II | Atezolizumab + Bevacizumab | A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma | Recruiting | USA | 0 |
| NCT03181100 | Phase II | Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | Active, not recruiting | USA | 0 |
| NCT04486352 | Phase Ib/II | Atezolizumab + Talazoparib Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab | A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer (EndoMAP) | Recruiting | USA | 0 |
| NCT05690048 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + Fecal microbiota + Vancomycin | Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) (FLORA) | Not yet recruiting | DEU | 0 |
| NCT04829383 | Phase II | Atezolizumab + Bevacizumab | A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma (AB7) | Recruiting | USA | 0 |
| NCT05448677 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + GNS561 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma (ABE-LIVER) | Recruiting | FRA | 0 |
| NCT05537402 | Phase II | Atezolizumab + Bevacizumab | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST- B) Trial (LOST-B) | Recruiting | USA | 0 |
| NCT04727307 | Phase II | Atezolizumab + Bevacizumab | Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial (AB-LATE02) | Recruiting | FRA | 0 |
| NCT04732286 | Phase III | Atezolizumab + Bevacizumab | A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy | Active, not recruiting | ESP | 0 |
| NCT04099836 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib | Terminated | USA | 0 |
| NCT05096715 | Phase I | Atezolizumab + Bevacizumab | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | Not yet recruiting | USA | 0 |
| NCT02921269 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer | Completed | USA | 0 |
| NCT05063552 | Phase II | Bevacizumab + Cisplatin + Docetaxel Carboplatin + Cetuximab + Docetaxel Bevacizumab + Carboplatin + Docetaxel Cetuximab + Cisplatin + Docetaxel Atezolizumab + Bevacizumab | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | Recruiting | USA | 0 |
| NCT02715531 | Phase I | Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | Completed | USA | AUS | 5 |
| NCT05482516 | Phase III | Atezolizumab + Bevacizumab | Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI) | Recruiting | USA | 0 |
| NCT05904886 | Phase III | Atezolizumab + Bevacizumab + Tiragolumab Atezolizumab + Bevacizumab | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14) | Recruiting | USA | ITA | FRA | ESP | CAN | 9 |
| NCT04857684 | Phase I | Atezolizumab + Bevacizumab | SBRT + Atezolizumab + Bevacizumab in Resectable HCC | Recruiting | USA | 0 |
| NCT04102098 | Phase III | Atezolizumab + Bevacizumab | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 17 |
| NCT05717400 | FDA approved | Atezolizumab + Bevacizumab | Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy | Recruiting | USA | 0 |
| NCT05620771 | Phase II | Yttrium-90 microsphere therapy Atezolizumab + Bevacizumab | Therasphere and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk | Recruiting | USA | 0 |
| NCT04541173 | Phase II | Atezolizumab + Bevacizumab | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) | Recruiting | USA | 0 |
| NCT05359861 | Phase II | Atezolizumab + Bevacizumab + SRF388 Atezolizumab + Bevacizumab | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | Recruiting | USA | AUS | 2 |
| NCT05528952 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + UCPVax | Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma (TERTIO) | Recruiting | FRA | 0 |
| NCT03818061 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (ATHENA) | Active, not recruiting | FRA | 0 |
| NCT04563338 | Phase II | Atezolizumab Atezolizumab + Bevacizumab | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | Recruiting | CAN | 0 |
| NCT02982694 | Phase II | Atezolizumab + Bevacizumab | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer | Terminated | ITA | ESP | BEL | 1 |
| NCT05185505 | FDA approved | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | Recruiting | USA | 0 |
| NCT04739202 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Ipatasertib | Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (IMMUNOGAST) | Unknown status | FRA | 0 |
| NCT05776875 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | Recruiting | USA | 0 |
| NCT04931342 | Phase II | Cobimetinib Ado-trastuzumab emtansine Ipatasertib + Paclitaxel Atezolizumab + Bevacizumab | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 5 |
| NCT05908786 | Phase Ib/II | Bevacizumab + RO7247669 Atezolizumab + Bevacizumab + Tiragolumab Atezolizumab + Bevacizumab | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | Recruiting | USA | 1 |
| NCT04721132 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | Recruiting | USA | 0 |
| NCT04487067 | Phase III | Atezolizumab + Bevacizumab | A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista (AMETHISTA) | Active, not recruiting | ITA | 0 |
| NCT04524871 | Phase Ib/II | Atezolizumab + Bevacizumab + Tocilizumab Atezolizumab + Bevacizumab + Tiragolumab Atezolizumab + Bevacizumab | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | Recruiting | USA | FRA | 5 |
| NCT05665348 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Bevacizumab + Ipilimumab | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET) | Not yet recruiting | FRA | 0 |
CKB BOOST